CTX-471: Clinical Trials

2 trials of CTX-471, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Recruiting 2
Phase 11Recruiting 1

Follow CTX-471: new trials by email Literature Review of CTX-471 trials Research Report on CTX-471

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
CTX-471 - Neuroendocrine Neoplasm, Neuroendocrine Carcinomas
Phase 2RecruitingCompass Therapeutics582026-11-012026-11-09
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
CTX-009, CTX-471 - Glioblastoma
Phase 1 / Phase 2RecruitingWashington University School of Medicine542026-06-162026-06-22

Conditions studied

Carcinoma, Neuroendocrine (1)  ·  Glioblastoma (1)  ·  Neuroendocrine Tumors (1)

Sponsors

Compass Therapeutics (1)  ·  Washington University School of Medicine (1)

Countries

United States (2)

Top investigators

Tanner M Johanns, MD, PhD (1)